Scientific programme

The scientific programme is structured around basic science, translational medicine and clinical sessions, given by some of the world’s top specialists. It also includes oral presentations of the best abstracts, the announcement of ECCO Fellowships and Grants and summary presentations of new ECCO Guidelines.  The focus of all sessions is clinical practice founded on science, with practical messages to take home.
Scientific sessions are held from Thursday, February 19, 2015 to Saturday, February 21, 2015. No parallel sessions are scheduled. The congress registration fee includes access to all scientific sessions.

Scientific programme

Bringing science, therapy & quality to patients

  • Plenary hall

      10:45-11:15 Top tips for chairs (Closed session)
    Larry Egan, Galway, Ireland
    Industry sponsored satellite symposia 1a & 1b
      12:45-12:50 Opening
    Eugeni Domènech Moral, Barcelona, Spain
      12:50-13:00 Welcome
    Séverine Vermeire, Leuven, Belgium
    Scientific session 1: The exposome in the pathogenesis of IBD
    Arie Levine, Holon, Israel
    Isabelle Cleynen, Leuven, Belgium
      13:00-13:20 How food triggers inflammation
    Marc Veldhoen, Cambridge, United Kingdom
      13:20-13:30 Best abstract: Transmissive Crohn’s Disease-like ileitis is caused by functional dysbiosis in the intestinal microbiota independent of inflammation-driven Paneth cell failure 
    M. Schaubeck¹, T. Clavel², I. Lagkouvardos¹, J. Calasan¹, S.B. Haange³,
    N. Jehmlich³, M. von Bergen⁴, M. Basic⁵, A. Bleich⁵, D. Haller²
    ¹Technische Universität München, Chair of Nutrition and
    Immunology, Weihenstephan, Germany, ²Technische Universität
    München, Chair of Nutrition and Immunology, Freising-
    Weihenstephan, Germany, ³Helmholtz-Centre for Environmental
    Research, UFZ, Department of Proteomics, Leipzig, Germany,
    ⁴University of Aalborg, Department of Biotechnology, Aalborg,
    Denmark, ⁵Hannover Medical School, Institute for Laboratory
    Anim, Hannover, Germany
      13:30-13:50 Impact of lifestyle changes on disease course
    Gerhard Rogler, Zurich, Switzerland
      13:50-14:00 Best abstract: UK IBD twin and multiplex registry: Concordance and environmental risk factors of twins with IBD
    H. Gordon¹, T. Orchard², A. Steel¹, M. Harbord¹
    ¹Chelsea and Westminster Hospital, Gastroenterology, London,
    United Kingdom, ²St Mary’s Hospital, Gastroenterology, London,
    United Kingdom
      14:00-14:10 Best abstract: Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial
    N. Rossen¹, S. Fuentes², M. van der Spek¹, J. Tijssen³, J. Hartman², A.
    Duflou¹, L. Mathus-Vliegen¹, W. de Vos², E. Zoetendal², G. D’Haens¹,
    C. Ponsioen¹
    ¹Academic Medical Centre, Gastroenterology & Hepatology,
    Amsterdam, Netherlands, ²Wageningen University, Laboratory
    of Microbiology, Wageningen, Netherlands, ³Academic Medical
    Centre, Cardiology, Amsterdam, Netherlands
      14:10-14:30 Epigenetics of IBD
    Jack Satsangi, Edinburgh, United Kingdom
    14:30-15:00 Coffee break 
    15:00-17:00 Scientific session 2: Pharmacokinetics in clinical practice: Does it matter?
    Geert D’Haens, Amsterdam, The Netherlands
    Eugeni Doménech, Barcelona, Spain
      15:00-15:20 Influence of the inflammatory burden on pharmacokinetics of biologicals
    Diane Mould, Phoenixville, United States
      15:20-15:30 Best abstract: Adalimumab and infliximab levels in neonates
    M. Julsgaard¹, ²
    , L.A. Christensen¹, P.R. Gibson³, R. Gearry⁴, J.
    Fallingborg⁵, J. Kjeldsen⁶, S. Wildt⁷, L. Svenningsen⁸, W. Connell²,
    C.L. Hvas¹, M.P. Sparrow³, A. Walsh⁹, S.J. Connor¹⁰, G. Radford-Smith¹¹,
    I. Lawrence¹², J.M. Andrews¹³, K. Ellard¹⁴, O. Rosella³, A. Grosen¹, J.
    Santamaria¹⁵, S.J. Bell²
    ¹Aarhus University Hospital, Department of Hepatology and
    Gastroenterology, Aarhus, Denmark, ²St Vincent’s Hospital &
    University of Melbourne, Department of Gastroenterology,
    Melbourne, Australia, ³Alfred Hospital and Monash University,
    Department of Gastroenterology, Melbourne, Australia, ⁴University
    of Otago, Christchurch Hospital, Department of Medicine and
    Gastroenterology, Christchurch, New Zealand, ⁵Aalborg Hospital,
    Department of Gastroenterology, Aalborg, Denmark, ⁶Odense
    University Hospital, Department of Gastroenterology and
    Hepatology, Odense, Denmark, ⁷Koege Hospital, Department
    of Gastroenterology, Koege, Denmark, ⁸Herning Hospital,
    Department of Medicine and Gastroenterology, Herning, Denmark,
    ⁹St. Vincent’s Hospital, Department of Gastroenterology, Sydney,
    Australia, ¹⁰Liverpool Hospital & University of NSW, Department
    of Gastroenterology, Sydney, Australia, ¹¹Royal Brisbane &
    Women’s Hospital, Department of Gastroenterology, Brisbane,
    Australia, ¹²Fremantle Hospital, Centre for Inflammatory Bowel
    Disease, Fremantle, Australia, ¹³Royal Adelaide Hospital, University
    of Adelaide, IBD Service, Department of Gastroenterology &
    Hepatology & School of Medicine, Adelaide, Australia, ¹⁴Royal
    North Shore Hospital, Department of Gastroenterology, Sydney,
    Australia, ¹⁵St Vincent’s Hospital & University of Melbourne,
    Department of Intensive Care, Melbourne, Australia
      15:30-15:50 Understanding pharmacokinetics and immunogenicity of anti-TNF
    Ann Gils, Leuven, Belgium
      15:50-16:00 Best abstract: Infliximab trough level thresholds vary depending on the efficacy criterion chosen in IBD patients
    X. Roblin¹, M. Rinaudo², C. Jarlot¹, E. Del Tedesco¹, J.M. Phelip¹, L.
    Clavel¹, L. Peyrin-Biroulet³, S. Paul²
    ¹University Hospital, Gastroenterology, Saint Etienne, France,
    ²University of Saint Etienne, Immunology, Saint Etienne, France,
    ³CHU de Nancy, Department of Gastroenterology, Vandoeuvre-les-
    Nancy, France
      16:00-16:10 Best abstract: Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary nonresponse to infliximab in Crohn’s Disease patients
    T. Billiet¹, I. Cleynen¹, V. Ballet², K. Claes¹, F. Princen³, S. Singh³, M.
    Ferrante², G. van Assche², S. Vermeire²
    ¹Department of Clinical and Experimental Medicine, KU Leuven,
    Translational Research in Gastrointestinal Disorders, Leuven,
    Belgium, ²University Hospitals Leuven, Gastroenterology -
    Translational Research Center for Gastrointestinal Disorders
    (TARGID), Leuven, Belgium, ³Prometheus Laboratories, Department
    of Research and Development, San Diego, United States
      16:10-16:30 Applying pharmacokinetics in the daily care of patients: from combination therapy to therapeutic drug monitoring
    Barrett Levesque, San Diego, United States
      16:30-16:40 Best abstract: Deep remission in Crohn’s Disease does not prevent disease relapse after withdrawal of anti-TNFα therapy
    M. Bortlik¹, D. Duricová¹, N. Machkova¹, V. Hruba¹, M. Lukas¹, K.
    Mitrova¹, I. Romanko¹, V. Bina², M. Lukas¹
    ¹ISCARE and Charles University, IBD Clinical and Research Centre,
    Prague, Czech Republic, ²Faculty of Management in Jindrichuv
    Hradec, University of Economics in Prague, Department of Exact
    Methods, Jindrichuv Hradec, Czech Republic
      16:40-17:00 Applying the lessons learnt from anti-TNF strategies to novel biologics
    Yehuda Chowers, Haifa, Israel
    17:15-18:15 Digital oral presentations on Level 1
  • Plenary hall

    07:15-08:15 Industry sponsored satellite symposia 3a & 3b
    08:30-09:30 Scientific session 3: Optimal use of resources
    Anna Kohn, Rome, Italy
    John Mansfield, Newcastle upon Tyne, United Kingdom
      08:30-08:50 The true cost of IBD care
    Keith Bodger, Liverpool, United Kingdom
      08:50-09:00 Best abstract: The first prospective Australian populationbased study of newly diagnosed IBD identifies frequent use of immunomodulators, low surgery rates and high cost from medications and investigations 
    O. Niewiadomski¹, C. Studd¹, C. Hair², J. Wilson¹, J. Ding¹, N.
    Heerasing², A. Ting², K. Ross², J. Santamaria³, E. Prewett², P.
    Dabkowski², S. Alexander², D. Dowling², B. Allen², B. Popp⁴, G. Alex⁵,
    T. Catto-Smith⁵, J. McNeill⁶, W. Connell¹, P. Desmond¹, S. Bell¹
    ¹St Vincent’s Hospital, Gastroenterology, Fitzroy, Australia, ²Barwon
    Health, Gastroenterology, Geelong, Australia, ³St Vincent’s
    Hospital, Intensive Care Unit, Fitzroy, Australia, ⁴St John of God
    Pathology, Pathology, Geelong, Australia, ⁵Royal Children’s
    Hospital, Gastroenterology, Parkville, Australia, ⁶Monash University,
    Preventative Medicine and Public Health, Melbourne, Australia
      09:00-09:10 Best abstract: Unchanged surgery and hospitalisation rates in an East-West European inception cohort despite differences in use of biologicals – 3-year follow-up of the ECCO-EpiCom cohort 
    J. Burisch¹, I. Kaimakliotis², D. Duricova³, L. Kievit⁴, J.F. Dahlerup⁵,
    R. Salupere⁶, K.R. Nielsen⁷, P. Manninen⁸, E.V. Tsianos⁹, Z. Vegh¹⁰,
    S. Odes¹¹, R. D’Inca¹², L. Kupcinskas¹³, S. Turcan¹⁴, F. Magro¹⁵, ¹⁶, ¹⁷, A.
    Goldis¹⁸, V. Hernandez¹⁹, J. Halfvarson²⁰, N. Arebi²¹, E. Langholz²², P.
    Lakatos¹⁰, P. Munkholm²³
    ¹Hvidovre University Hospital, Gastroenterology, Medical section,
    Hvidovre, Denmark, ²Nicosia Private Practice, Nicosia, Cyprus,
    ³Charles University, IBD Center ISCARE, Prague, Czech Republic,
    ⁴Herning Central Hospital, Department of Medicine, Herning,
    Denmark, ⁵Aarhus University Hospital, Department of Hepatology
    and Gastroenterology, Aarhus, Denmark, ⁶Tartu University Hospital,
    Division of Endocrinology and Gastroenterology, Tartu, Estonia,
    ⁷The National Hospital of the Faroe Islands, Medical Department,
    Thorshavn, Faroe Islands, ⁸Tampere University Hospital,
    Department of Gastroenterology and Alimentary Tract Surgery,
    Tampere, Finland, ⁹University Hospital, Ioannina, 1st Division of
    Internal Medicine and Hepato-Gastroenterology Unit, Ioannina,
    Greece, ¹⁰Semmelweis University, 1st Department of Medicine,
    Budapest, Hungary, ¹¹Soroka Medical Center and Ben Gurion
    University of the Negev, Department of Gastroenterology and
    Hepatology, Beer Sheva, Israel, ¹²On behalf of the EpiCom Northern
    Italy, Florence, Forlì, and Padova, Italy, ¹³Lithuanian University of
    Health Sciences, Institute for Digestive Research, Kaunas, Lithuania,
    ¹⁴State University of Medicine and Pharmacy of the Republic of
    Moldova, Department of Gastroenterology, Chisinau, Republic
    of Moldova, ¹⁵University of Porto, Institute for Molecular and Cell
    Biology, Porto, Portugal, ¹⁶Hospital de São João, Department
    of Gastroenterology, Porto, Portugal, ¹⁷Oporto Medical School,
    Institute of Pharmacology and Therapeutics, Porto, Portugal,
    ¹⁸University of Medicine ‘Victor Babes’, Clinic of Gastroenterology,
    Timisoara, Romania, ¹⁹Complexo Hospitalario Universitario de Vigo,
    Gastroenterology Department, Vigo, Spain, ²⁰Faculty of Medicine
    and Health, Örebro University, Department of Gastronterology,
    Örebro, Sweden, ²¹St Mark’s Hospital, Gastroenterology, London,
    United Kingdom, ²²Gentofte Hospital, Department of Medical
    Gastroenterology, Copenhagen, Denmark, ²³Herlev University
    Hospital, Department of Gastroenterology, Herlev, Denmark
      09:10-09:30 Surgical alternatives to biological therapy
    Omar Faiz, London, United Kingdom
    09:30-10:30 Scientific session 4: The gut barrier under attack: Therapeutic implications
    Silvio Danese, Milan, Italy
    Philippe Marteau, Paris, France
      09:30-09:50 Mechanisms of damage and repair
    Gijs van den Brink, Amsterdam, The Netherlands
      09:50-10:00 Best abstract: Medication-induced microscopic colitis: Do recency and duration of use matter?
    B.P.M. Verhaegh¹, ², F. de Vries³, ⁴, A.A. Masclee¹, ², A. Keshavarzian³, A.
    de Boer³, P. Souverein³, D.M. Jonkers¹, ², M.J. Pierik¹
    ¹Maastricht University Medical Center, Internal Medicine - Division
    of Gastroenterology-Hepatology, Maastricht, Netherlands,
    ²Maastricht University Medical Center, NUTRIM, School for
    Nutrition, Toxicology and Metabolism, Maastricht, Netherlands,
    ³Utrecht Institute of Pharmaceutical Sciences, Division of
    Pharmacoepidemiology and Clinical Pharmacology, Utrecht,
    Netherlands, ⁴Maastricht University Medical Center, Clinical
    Pharmacology & Toxicology, Maastricht, Netherlands
      10:00-10:10 Best abstract: Budesonide MMX® 9 mg for inducing remission in patients with mild-to-moderate Ulcerative Colitis not adequately controlled with oral 5-ASAs 
    D.T. Rubin¹, R.D. Cohen¹, W.J. Sandborn², G.R. Lichtenstein³, J. Axler⁴,
    R. Riddell⁵, C. Zhu⁶, A.C. Barrett⁶, E. Bortey⁶, W.P. Forbes⁶
    ¹The University of Chicago, Medicine, Chicago, United States,
    ²University of California San Diego, UC San Diego Health System,
    San Diego, United States, ³University of Pennsylvania, Perelman
    School of Medicine, Philadelphia, United States, ⁴Toronto Digestive
    Disease Associates Inc., Toronto, Canada, ⁵Mount Sinai Hospital,
    Pathology and Molecular Medicine, Toronto, Canada, ⁶Salix
    Pharmaceuticals Inc., Raleigh, United States
      10:10-10:30 The microbiome in the pathogenesis and therapy of IBD
    Ailsa Hart, London, United Kingdom
    10:30-11:00 Coffee break
    11:00-12:20 Scientific session 5: Delivering quality to the patients
    Simon Travis, Oxford, United Kingdom
    Janette Gaarenstroom, Utrecht, The Netherlands
      11:00-11:20 The central role of the IBD nurse in the multidisciplinary management
    Marian O’Connor, London, United Kingdom
      11:20-11:30 Best abstract: Information needs and concerns of patients with Inflammatory Bowel Disease: What can we learn from participants of a national clinical cohort?
    V. Pittet¹, C. Vaucher¹, M.H. Maillard², M. Girardin³, P. de Saussure³, G.
    Rogler⁴, P. Michetti⁵
    ¹Institute of Social and Preventive Medicine, Healthcare Evaluation
    Unit, Lausanne, Switzerland, ²Lausanne University Hospital,
    Department of Gastroenterology & Hepatology, Lausanne,
    Switzerland, ³Geneva University Hospital, Division of Gastroenterology
    & Hepatology, Geneva, Switzerland, ⁴University of Zurich,
    Gastroenterology and Hepatology, Zurich, Switzerland, ⁵Clinique La
    Source-Beaulieu, Crohn and Colitis Center, Lausanne, Switzerland
      11:30-11:50 Measuring the quality performance of your centre
    Xavier Calvet Calvo, Sabadell, Spain
      11:50-12:00 Best abstract: Patient-relevant endpoints in Inflammatory Bowel Diseases – Have changes occurred in Germany over the past twelve years?
    A. Stallmach1, U. Dennler2, U. Marschall3, C. Schmidt1
    1University Hospital Jena, Clinic for Internal Medicine IV, Jena,
    Germany, 2Friedrich Schiller University Jena, Geschäftsbereich
    Medizincontrolling, Jena, Germany, 3BARMER GEK
    Hauptverwaltung 1100, Kompetenzzentrum Medizin und
    Versorgungsforschung, Berlin, Germany
      12:00-12:20 Panel discussion
    • Role of the IBD nurse in continued patient care?
    • Value of a transition clinic?
    • Follow-up of the pregnant IBD patient
    • Who should operate on the IBD patient?

    Simon Travis, Oxford, United Kingdom
    Ronan O’Connell, Dublin, Ireland
    Zuzana Zelinkova, Bratislava, Slovakia
    Hankje Escher, Rotterdam, The Netherlands
    Marian O’Connor, London, United Kingdom 
    12:20-13:30 Lunch break
    Guided poster session
    Industry sponsored educational lunchtime satellite symposia LS1, LS2, LS3, LS4
    13:30-15:00 Scientific session 6: Anti-TNF: Originators & Biosimilars
    Gerassimos Mantzaris, Athens, Greece
    Gionata Fiorino, Milan, Italy
      13:30-13:50 The science behind biosimilars
    Gonzalo Calvo, Barcelona, Spain
      13:50-14:00 Best abstract: Use of anti-TNF-α agents in relation to firsttime surgery for Ulcerative Colitis and Crohn’s Disease during childhood
    M.D. Larsen1, J. Kjeldsen2, N. Qvist3, B. Nørgård1, J. Nielsen1
    1Odense University Hospital, Clinical Epidemiology, Odense,
    Denmark, 2Odense Hospital, Department of Medical
    Gastroenterology S, Odense, Denmark, 3Odense University
    Hospital, Surgical Department, Odense, Denmark
      14:00-14:20 Experience with biosimilars from rheumatology
    Ulf Müller-Ladner, Bad-Nauheim, Germany
      14:20-14:30 Best abstract: Multicentre clinical trial with topical administration of the toll-like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis
    R. Atreya1, S. Bloom2, F. Scaldaferri3, V. Gerardi3, A. Karlsson4,
    T. Knittel4, J. Kowalski4, M. Lukas5, R. Lofberg6, R. Petryka7, G.
    Rydzewska8, R. Schnabel9, U. Seidler10, S. Nancey11, M. Neurath12,
    C. Hawkey13
    1University of Erlangen-Nuremberg, Department of Medicine
    1, Erlangen, Germany, 2University College London Hospital,
    Gastroenterology, London, United Kingdom, 3Catholic University
    of Rome, Internal Medicine/Gastroenterology Division, Rome, Italy,
    4InDex Pharmaceuticals, Clinical Research, Stockholm, Sweden,
    5Clinical Centre Iscare Lighthouse, IBD Clinical & Research Centre,
    Prague, Czech Republic, 6Karolinska Institute and Sophiahemmet,
    Gastro Center, Stockholm, Sweden, 7NZOZ Vivamed,
    Gastroenterology, Warsaw, Poland, 8Central Clinical Hospital
    Ministry of Interior in Warsaw, Department of Gastroenterology,
    Warsaw, Poland, 9Pannonia Maganorvosi Centrum,
    Gastroenterology, Budapest, Hungary, 10MHH, Department of
    Gastroenterology, Hepatology and Endocrinology, Hannover,
    Germany, 11Lyon-Sud Hospital, Gastroenterology, Pierre-Benite,
    France, 12University of Erlangen-Nuremberg, Gastroenterology,
    Erlangen, Germany, 13University of Nottingham, Nottingham
    Digestive Diseases Centre, Nottingham, United Kingdom
      14:30-14:40 Best abstract: Treatment strategy during the first year after diagnosis in patients with Inflammatory Bowel Diseases from the 2011 ECCO-EpiCom inception cohort
    Z. Vegh1, J. Burisch2, E.V. Tsianos3, L. Kupcinskas4, S. Turcan5,
    F. Magro6, 7, 8, A. Goldis9, V. Hernandez10, S. Bell11, P. Munkholm12,
    P. Lakatos1
    1Semmelweis University, 1st Department of Medicine, Budapest,
    Hungary, 2Hvidovre University Hospital, Gastrounit, Medical
    section, Hvidovre, Denmark, 3University of Ioannina, 1st Division
    of Internal Medicine and Division of Gastroenterology, Faculty
    of Medicine, Ioannina, Greece, 4Lithuanian University of Health
    Sciences, Institute for Digestive Research, Kaunas, Lithuania,
    5State University of Medicine and Pharmacy, Department of
    Gastroenterology, Chisinau, Republic of Moldova, 6Hospital de São
    João, Department of Gastroenterology, Porto, Portugal, 7Oporto
    Medical School, Department of Pharmacology and Therapeutics,
    Porto, Portugal, 8University of Porto, 8MedInUP - Centre for Drug
    Discovery and Innovative Medicines, Porto, Portugal, 9University
    of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara,
    Romania, 10Complexo Hospitalario Universitario de Vigo,
    Gastroenterology Department, Vigo, Spain, 11St Vincent’s Hospital,
    Department of Gastroenterology, Melbourne, Victoria, Australia,
    12Herlev University Hospital, Digestive Disease Centre, Medical
    Section, Copenhagen, Denmark
      14:40-15:00 Unanswered questions on biosimilars in IBD
    Stefan Schreiber, Kiel, Germany
    15:00-15:30 Coffee break
    15:30-16:10 Scientific session 7: ECCO Fellowships and Grants
    Edouard Louis, Liège, Belgium
    Pieter Hindryckx, Gent, Belgium
      15:30-15:37 Outcomes from the 2013-14 Fellowships: The effect of vitamin D on
    the intestinal microbiome in patients with Ulcerative Colitis
    Mayur Garg, Victoria, Australia
      15:37-15:44 Outcomes from the 2013-14 Fellowships: Mechanisms of primary non-response
    to anti-TNF α therapy in Inflammatory Bowel Disease
    Konstantinos Papamichael, Athens, Greece
      15:44-15:50 Fellowships and Grants 2015
    Edouard Louis, Liège, Belgium
      15:50-16:00 Best abstract: Long-term outcomes in a cohort of patients with Acute Severe Ulcerative Colitis refractory to intravenous steroids treated with cyclosporine or infliximab
    D. Laharie1, A. Bourreille2, J. Branche3, M. Allez4, Y. Bouhnik5, J.
    Filippi6, F. Zerbib7, G. Savoye8, L. Vuitton9, J. Moreau10, A. Amiot11, J.
    Cosnes12, E. Ricart13, O. Dewit14, A. Lopez-Sanroman15, J.-L. Dupas16, F.
    Carbonnel17, G. Bommelaer18, B. Coffin19, X. Roblin20, G. van Assche21,
    M. Esteve22, M. Farkkila23, J.P. Gisbert24, P. Marteau25, S. Nahon26, M.
    de Vos27, J.-Y. Mary28, E. Louis29
    1Hopital Haut-Leveque, CHU de Bordeaux, Gastroenterology,
    Pessac, France, 2CHU de Nantes, Department of Gastroenterology,
    Nantes, France, 3CHU de Lille, Department of Gastroenterology,
    Lille, France, 4Hopital Saint-Louis, Gastroenterology, Paris,
    France, 5Hopital Beaujon, Gastroenterology, Clichy, France,
    6CHU de Nice, Gastroenterology, Nice, France, 7CHU de
    Bordeaux, Gastroenterology, Bordeaux, France, 8CHU de
    Rouen, Gastroenterology, Rouen, France, 9CHU de Besancon,
    Gastroenterology, Besancon, France, 10CHU de Toulouse,
    Gastroenterology, Toulouse, France, 11Hopital Henri-Mondor,
    Gastroenterology, Creteil, France, 12Hopital Saint-Antoine,
    Gastroenterology, Paris, France, 13Hospital Clinic, Gastroenterology,
    Barcelona, Spain, 14UCL Saint-Luc, Gastroenterology, Brussels,
    Belgium, 15Hospital Ramon y Cajal, Gastroenterology, Madrid,
    Spain, 16CHU d’Amiens, Gastroenterology, Amiens, France, 17Hopital
    du Kremlin-Bicetre, Gastroenterology, Le Kremlin-Bicetre, France,
    18CHU de Clermont-Ferrand, Gastroenterology, Clermont-Ferrand,
    France, 19Hopital Louis-Mourier, Gastroenterology, Colombes,
    France, 20CHU de Saint-Etienne, Gastroenterology, Saint-Etienne,
    France, 21University Hospital of Leuven, Gastroenterology,
    Leuven, Belgium, 22Hospital Universitari Mútua de Terrassa,
    Gastroenterology, Barcelona, Spain, 23Helsinki University
    Central Hospital, Gastroenterology, Helsinki, Finland, 24Hospital
    Universitario de La Princesa, Gastroenterology, Madrid, Spain,
    25Hopital Lariboisiere, Gastroenterology, Paris, France, 26Hopital
    de Montfermeil, Gastroenterology, Montfermeil, France, 27Ghent
    University Hospital, Gastroenterology, Ghent, Belgium, 28Hopital
    Saint-Louis, SBIM, Paris, France, 29Hopital Universitaire de Liège,
    Gastroenterology, Liège, Belgium
      16:00-16:10 Best abstract: Prolonged deep remission of ileocolonic Crohn’s Disease following Autologous Haemopoetic stem cell transplantation, presented on behalf of all the ASTIC Trialists
    C. Hawkey1, M. Allez2, M. Clark1, M. Labopin3, J. Lindsay4, E. Ricart5,
    G. Rogler6, J. Satsangi7, D. Farge-Bancel8
    1University of Nottingham, Nottingham Digestive Diseases
    Centre, Nottingham, United Kingdom, 2APHP, Hopital Saint
    Louis, Department of Gastroenterology, Paris, France, 3European
    Group for Blood & Marrow Transplantation, Chair-EBMT Statistical
    Committee, Paris, France, 4Blizard Institute, Barts & The London
    School of Medicine & Dentistry, Queen Mary University of London,
    Centre for Digestive Diseases, London, United Kingdom, 5Hospital
    Clinic, CIBER-EHD, Gastroenterology Department, Barcelona, Spain,
    6University of Zurich, Division of Gastroenterology & Hepatology,
    Zurich, Switzerland, 7Western General Hospital, University of
    Edinburgh, Gastro-Intestinal Unit, Edinburgh, United Kingdom,
    8APHP, Hopital Saint Louis, Internal Medicine & Vascular Disease
    Unit, Paris, France
    16:10-17:10 Scientific session 8: Challenging Cases
    Edouard Louis, Liège, Belgium
    Pierre Michetti, Lausanne, Switzerland
    Frank Ruemmele, Paris, France
      16:10-16:30 Case 1: Risk of cancer in chronic perianal disease
    Stephan Vavricka, Zurich, Switzerland
      16:30-16:50 Case 2: Risk of infection occuring under biological treatment
    Thomas Billiet, Leuven, Belgium
      16:50-17:10 Case 3: Loss of response to anti-TNF in paediatrics
    Malgorzata Sladek, Krakow, Poland
    17:10-17:50 Scientific session 9: What's new on the guideline front?
    Vito Annese, Florence, Italy
    Tiago Nunes, Rio de Janeiro , Brazil
      17:10-17:20 ECCO Guidelines:Malignancy
    Rami Eliakim, Tel Aviv, Israel
      17:20-17:30 Best abstract: Forty-year analysis of colonoscopic surveillance for Ulcerative Colitis reveals decreasing risk of interval and advanced cancer and reducing colectomy rate for dysplasia
    C.H.R. Choi1, M. Rutter2, S. Thomas-Gibson3, J. Warusavitarne3, M.
    Moorghen3, B. Saunders3, T. Graham4, A. Hart3
    1St Mark’s Hospital, Colorectal Surgery & IBD Unit, London, United
    Kingdom, 2University Hospital of North Tees, Department of
    Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom,
    3St Mark’s Hospital, Department of IBD, Colorectal Surgery and
    Wolfson Unit of Endoscopy, London, United Kingdom, 4Queen
    Mary University of London, Centre for Tumour Biology, Barts
    Cancer Institute, London, United Kingdom
      17:30-17:40 Best abstract: Patients with Inflammatory Bowel Disease and a history of cancer: The risk of cancer following exposure to immunosuppression
    J. Axelrad1, O. Bernheim2, J.-F. Colombel2, S. Malerba3, A.
    Ananthakrishnan4, V. Yajnik4, G. Hoffman5, M. Agrawal6, D. Lukin7, A.
    Desai8, E. Mceachern9, B. Bosworth8, E. Scherl8, A. Reyes10, H. Zaidi11,
    P. Mudireddy12, D. DiCaprio13, K. Sultan11, B. Korelitz12, E. Wang14, R.
    Williams14, L. Chen15, S. Katz15, S. Itzkowitz2
    1Icahn School of Medicine at Mount Sinai, Medicine, New York,
    United States, 2Icahn School of Medicine at Mount Sinai, Division
    of Gastroenterology, New York, United States, 3Icahn School of
    Medicine at Mount Sinai, Department of Health Evidence and
    Policy, New York, United States, 4Massachusetts General Hospital,
    Division of Gastroenterology, Boston, United States, 5Albert
    Einstein College of Medicine, Medicine, New York, United States,
    6Montefiore Medical Center, Medicine, New York, United States,
    7Montefiore Medical Center, Division of Gastroenterology and
    Liver Diseases, New York, United States, 8New York Presbyterian
    Weill Cornell Medical Center, Division of Gastroenterology, New
    York, United States, 9Weill Cornell Medical College, Medicine, New
    York, United States, 10North Shore-Long Island Jewish University
    Hospital, Medicine, Manhasset, United States, 11North Shore-Long
    Island Jewish University Hospital, Division of Gastroenterology,
    Manhasset, United States, 12North Shore-Long Island Jewish Lenox
    Hill Hospital, Division of Gastroenterology, New York, United States,
    13North Shore-Long Island Jewish Lenox Hill Hospital, Medicine,
    New York, United States, 14NYU Langone Medical Center, Medicine,
    New York, United States, 15NYU Langone Medical Center, Division
    of Gastroenterology, New York, United States
      17:40-17:50 Extra-intestinal manifestations
    Franck Carbonnel, Le Kremlin-Bicetre, France
    Marcus Harbord, London, United Kingdom
    18:00-19:00 Industry sponsored satellite symposia 4a & 4b
  • Plenary hall

    07:15-08:15 Industry sponsored satellite symposia 5a & 5b (TBC)
    08:30-10:20 Scientific session 10: New therapies and strategies
    Laurent Peyrin-Biroulet, Nancy, France
    Krisztina Gecse, Budapest, Hungary
      08:30-08:50 New algorithms for treating IBD
    Gert van Assche, Leuven, Belgium
      08:50-09:00 Best abstract: TURANDOT: A randomised, multicentre double-blind, placebo-controlled study of the safety and efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC)
    S. Vermeire1, W. Sandborn2, S. Danese3, X. Hebuterne4, B. Salzberg5,
    M. Klopocka6, D. Tarabar7, T. Vanasek8, M. Gregus9, P. Hellstern10, J.-S.
    Kim11, M. Sparrow12, K.J. Gorelick13, A. Ahmad14, M. Hassan-Zahraee14,
    V. Pradhan14, F. Cataldi14, W. Reinisch15
    1Leuven University Hospital, Leuven, Belgium, 2University of
    California San Diego, San Diego, United States, 3IBD-Division
    Gastroenterology, Istituto Clinico Humanitas, Rozzano, Italy,
    4Hospital l’Archet, Nice Cedex, France, 5Atlanta Gastroenterology
    Specialist, Suwanee, United States, 6University Hospital, Nicolaus
    Copernicus University, Torun Bydgoszcz, Poland, 7Military Medical
    Academy, Belgrade, Serbia, 8Hepato-Gastroenterology, Hradec
    Kralove, Czech Republic, 9Gastroenterologicke a hepatologicke,
    Nitra, Slovakia, 10Nature Coast Clinical Research, Inverness, Florida,
    United States, 11Seoul National University Hospital, Seoul, South
    Korea, 12Alfred Hospital of Melbourne, Melbourne, Australia, 13Pfizer
    Inc., Collegeville, United States, 14Pfizer Inc., Cambridge, United
    Kingdom, 15McMaster University Health Centre, Ontario, Canada
      09:00-09:10 Best abstract: Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s Disease: Results of the OPERA study
    G. D’Haens1, S. Lee2, D. Tarabar3, E. Louis4, M. Klopocka5, D.I. Park6,
    J. Claus7, X. Hébuterne8, W. Reinisch9, S. Schreiber10, K.J. Gorelick11, J.
    Cheng11, M. Hassan-Zahraee11, L. Brown11, A. Ahmad11, A. Banerjee11,
    F. Cataldi11, W. Sandborn12
    1University of Amsterdam, Academic Medical Center, Amsterdam,
    Netherlands, 2University of Washington, Gastroenterology,
    Seattle, WA, United States, 3MMA, Gastroenterology, Belgrade,
    Serbia, 4University Hospital CHU of Liège, Gastroenterology,
    Liège, Belgium, 5Nicolaus Copernicus University in Toruń,
    Gastroenterology, Bydgoszcz, Poland, 6Kangbuk Samsung
    Hospital-Sungkyunkwan University, Gastroenterology, Seoul,
    South Korea, 7Universitätsklinikum Ulm, Gastroenterology, Ulm,
    Germany, 8CHU de Nice et Université de Nice Sophia-Antipolis,
    Gastroenterology, Nice, France, 9Medical University of Vienna,
    Internal Medicine/Gastroenterology, Vienna, Austria, 10University of
    Kiel, Gastroenterology, Kiel, Germany, 11Pfizer Inc., Gastroenterology,
    Cambridge, United States, 12University of California San Diego,
    Division of Gastroenterology, San Diego, United States
      09:10-09:20 Best abstract: Methotrexate for corticosteroid-dependent Ulcerative Colitis: Results of a placebo randomised controlled trial
    F. Carbonnel1, J.F. Colombel2, J. Filippi3, K. Katsanos4, L. Peyrin-
    Biroulet5, M. Allez6, M. Nachury7, 8, G. Novacek9, S. Danese10, V.
    Abitbol11, F. Bossa12, J. Moreau13, G. Bommelaer14, A. Bourreille15, J.L.
    Dupas16, X. Roblin17, Y. Bouhnik18, W. Reinisch9, 19, M. Farkkila20, H.
    Brixi21, P. Seksik22, G. Malamut23, B. Coulibaly24, O. Dewit25, E. Louis26,
    D. Deplanque27, P. Michetti28, H. Sarter27, D. Laharie29
    1APHP Paris Sud University, Gastroenterology, Le Kremlin Bicêtre,
    France, 2Icahn Medical School of Medicine at Mount Sinai, IBD
    Center, New York, United States, 3University Hospital of Nice
    Archet 2, Gastroenterology, Nice, France, 4University of Ioannina
    School of Medical Sciences, Gastroenterology, Ioannina, Greece,
    5University Hospital of Nancy, Gastroenterology, Nancy, France,
    6Saint Louis Hospital APHP, Gastroenterology, Paris, France,
    7University Hospital of Lille, Gastroenterology, Lille, France,
    8University Hopsital of Besançon, Gastroenterology, Besançon,
    France, 9Medizinische Universität Wien, Gastroenterology,
    Vienna, Austria, 10Istituto Clinico Humanitas, Gastroenterology,
    Milano, Italy, 11Cochin University Hospital, Gastroenterology,
    Paris, France, 12Cancer Research and Cure Institute “Casa Sollievo
    Sofferenza”, Gastroenterology, San Giovanni Rotondo, Italy,
    13Rangueil University Hospital, Gastroenterology, Toulouse, France,
    14University Hospital of Clermont Ferrand, Gastroenterology,
    Clermont Ferrand, France, 15Insitut des Maladies de l’Appareil
    Digestif, Gastroenterology, Nantes, France, 16Amiens University
    Hospital, Gastroenterology, Amiens, France, 17University Hospital
    of Saint Etienne, Gastroenterology, Saint Etienne, France,
    18University Hospital of Beaujon APHP, Gastroenterology, Clichy,
    France, 19McMaster University, Gastroenterology, Hamilton,
    Canada, 20University Hospital of Helsinki, Gastroenterology,
    Helsinki, Finland, 21University Hospital of Reims, Gastroenterology,
    Reims, France, 22University Hospital of Saint Antoine, APHP,
    Gastroenterology, Paris, France, 23Hôpital Européen Georges
    Pompidou, APHP, Gastroenterology, Paris, France, 24General
    Hospital of Avignon, Gastroenterology, Avignon, France, 25UCL
    Saint Luc, Gastroenterology, Brussels, Belgium, 26University Hospital
    of Liège, Gastroenterology, Liège, Belgium, 27University Hospital of
    Lille, Biostatistics and Clinical Research, Lille, France, 28Clinique de
    la Source, Gastroenterology, Lausanne, Switzerland, 29University
    Hospital of Bordeaux, Gastroenterology, Bordeaux, France
      09:20-09:40 Positioning of the new molecules in practice
    Brian Feagan, London, Canada
      09:40-09:50 Best abstract: A randomised, double-blind, placebocontrolled induction trial of an oral S1P receptor modulator (RPC1063) in moderate to severe Ulcerative Colitis: Results of the TOUCHSTONE study
    W. Sandborn1, B. Feagan2, D. Wolf3, G. D’Haens4, S. Vermeire5, S.
    Hanauer6, S. Ghosh7, H. Smith8, M. Cravets8, P. Frohna8, S. Gujrathi8,
    A. Olson8
    1University of California San Diego, Division of Gastroenterology,
    La Jolla, United States, 2University of Western Ontario, Department
    of Gastroenterology, London, Canada, 3Atlanta Gastroenterology
    Associates, Emory Saint Joseph’s, Atlanta, United States,
    4Academic Medical Centre, Inflammatory Bowel Disease
    Centre, Amsterdam, Netherlands, 5University Hospital Leuven,
    Department of Gastroenterology, Leuven, Belgium, 6Northwestern
    University Feinberg School of Medicine, Digestive Health Center,
    Chicago, United States, 7University of Calgary, Department
    of Gastroenterology, Alberta, Canada, 8Receptos, Inc., Clinical
    Development, San Diego, United States
      09:50-10:00 Best abstract: A randomised, double-blind placebocontrolled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn’s Disease who have failed anti-TNF antibody therapy
    B.E. Sands1, J. Chen2, M. Penney2, P. Newbold2, R. Faggioni2, R. van
    der Merwe2, K. Patra2, P. Klekotka3, E. Pulkstenis2, J. Drappa2, R.A.
    Gasser, Jr.2
    1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz
    Division of Gastroenterology, New York, NY, United States,
    2MedImmune, Clinical Development, Gaithersburg, MD, United
    States, 3Amgen, Clinical Development, Thousand Oaks, CA, United
      10:00-10:20 New surgical techniques
    Willem Bemelman, Amsterdam, The Netherlands
    10:20-10:50 Coffee break
    10:50-12:20 Scientific session 11: Managing the manageable: Chronic pain and fatigue
    Eduard Cabré, Barcelona, Spain
    Igor Khalif, Moscow, Russia
      10:50-11:10 Joint pain: arthritis and arthralgias
    Juan Jesús Gómez Reinó, Santiago, Spain
      11:10-11:30 Algorithm for abdominal pain management
    Andreas Sturm, Berlin, Germany
      11:30-11:50 Algorithm for the management of fatigue
    Janneke van der Woude, Rotterdam, The Netherlands
      11:50-12:00 Best abstract: Post-operative use of anti-TNFα agents in patients with Crohn’s Disease and risk of re-operation – A nationwide cohort study
    J. Kjeldsen1, J. Nielsen2, M.D. Larsen2, N. Qvist3, B. Nørgaard2
    1University of Southern Denmark, Department of Medical
    Gastroenterology, Odense University Hospital and Research Unit
    of Gastroenterology, Odense, Denmark, 2University of Southern
    Denmark, Center for Clinical Epidemiology, Odense University
    Hospital and Research Unit of Clinical Epidemiology, Institute
    of Clinical Research, Odense, Denmark, 3University of Southern
    Denmark, Department of Surgery, Odense University Hospital and
    Research Unit of Surgery, Institute of Clinical Research, Odense,
      12:00-12:10 Best abstract: The rising incidence of early-onset paediatric Inflammatory Bowel Disease (Paris A1a) in Scotland since 1981: A national, population-based, cohort study
    P. Henderson1, F.L. Cameron1, F. Jagger2, R. Hansen3, H. Drummond4,
    E. Reynish5, S. Loganathan2, R.K. Russell3, J. Satsangi4, D.C. Wilson1
    1University of Edinburgh, Child Life and Health, Edinburgh, United
    Kingdom, 2Royal Aberdeen Children’s Hospital, Department of
    Paediatric Gastroenterology, Aberdeen, United Kingdom, 3Royal
    Hospital for Sick Children, Paediatric Gastroenterology, Glasgow,
    United Kingdom, 4University of Edinburgh, Gastrointestinal Unit,
    Centre for Genomic and Experimental Medicine, Edinburgh,
    United Kingdom, 5University of Stirling, School of Applied Social
    Science, Stirling, United Kingdom
      12:10-12:20 Best abstract: Oral delivery of a new class of non-antibody protein scaffold nanofitins targeting TNF-alpha shows a strong preventive and curative anti-inflammatory effect in models of Inflammatory Bowel Diseases
    M. Cinier1, M. Zeisser Labouèbe2, C. Rousseaux3, J.V.Rodrigues4, A.
    Cunha4, N. Truong Tan3, R. Gurny2, L. Scapozza2, O. Kitten1
    1Affilogic, Nantes, France, 2University of Geneva, School of
    Pharmaceutical Sciences, Geneva, Switzerland, 3Intestinal Biotech
    Development, Lille, France, 4Instituto de Biologia Experimental
    Tecnológica, iBET, Oeiras, Portugal
    12:20-12:50 Scientific session 12: ECCO Lecture
    Séverine Vermeire, Leuven, Belgium
    Julian Panés, Barcelona, Spain
      12:20-12:50 The science which will impact our IBD clinic
    Maria Abreu, Miami, United States
    12:50-12:55 Awards and closing remarks
    Séverine Vermeire, Leuven, Belgium
    The ECCO Film 2015